Bio- and Pharmaanalysis

Novel CRISPR-Cas genome-editing nucleases can be used to modify genetic material in cells by specifically altering genes and inserting them into the genome or by removing them altogether.

Biontech aims to develop the first mRNA-based vaccine for Malaria prevention with the initiation of a clinical trial by end of 2022.

First author Yong-Hyun Han, PhD, (left) and co-author and Washington University surgical resident Emily Onufer, MD, work in the surgical suite where the mouse surgeries were conducted as part of this study.

With the first cancer cell model, researchers at TU Graz were able to launch an essential tool for modern cancer research and drug development. Pictured: a graphical representation of a dividing cancer cell.

Waters expands its existing collaboration with the Bioprocessing Technology Institute, A*Star into new areas meant to accelerate bioprocessing and bioinformatics research.

Two pMUT sensors integrated in an ultrasound probe demonstrator.

Researchers at Chalmers University of Technology, Sweden, have succeeded in developing a method to label mRNA molecules.

With “Chemistry in Water”, Evonik now offers the possibility of carrying out classic organic reactions in water.

Unfold for details of your consent

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.